Sequencing chemotherapy before radiotherapy for women with stage IIIC endometrial cancer. Issue 5 (May 2021)
- Record Type:
- Journal Article
- Title:
- Sequencing chemotherapy before radiotherapy for women with stage IIIC endometrial cancer. Issue 5 (May 2021)
- Main Title:
- Sequencing chemotherapy before radiotherapy for women with stage IIIC endometrial cancer
- Authors:
- Narasimhulu, Deepa Maheswari
Block, Matthew S
Weaver, Amy L
McGree, Michaela
Kumar, Amanika
Langstraat, Carrie
Petersen, Ivy
Mariani, Andrea
Glaser, Gretchen - Abstract:
- Abstract : Objective : It is unclear how to best sequence adjuvant chemotherapy and radiotherapy for advanced endometrial cancer. We studied the outcomes for women treated with chemotherapy before radiotherapy in a chemotherapy‐first (chemotherapy for 6 cycles followed radiotherapy) or 'sandwich' approach (chemotherapy for 3 cycles followed by radiotherapy and subsequently chemotherapy for 3 cycles). Methods : Women with stage IIIC endometrial cancer and no gross residual disease treated with chemotherapy before radiotherapy between April 2003 and April 2016 were included. The Kaplan‐Meier method was used to estimate recurrence and survival. We performed a meta‐analysis of endometrial cancer trials comparing chemotherapy and radiotherapy versus radiotherapy alone. Results : A total of 102 patients were included. The mean (SD) age was 63.8 (10.6) years; 84 patients received the chemotherapy‐first approach and 18 patients received the 'sandwich' approach. Pelvic and para‐aortic nodes were removed in 99% and 88.2%, respectively. Among all the patients, we observed 1 pelvic (1%), 1 para‐aortic (1%), and 5 vaginal (4.9%) recurrences. At 3 years, for the 'sandwich' and chemotherapy‐first approaches, the vaginal recurrence was 11.8% and 4.2%, pelvic recurrence was 0% and 1.5%, para‐aortic recurrence was 0% and 1.2%, distant recurrence was 42.9% and 24.4%, and overall survival was 70.3% and 81.7%, respectively. With 'chemotherapy before radiotherapy' 94.9% completed 4+ chemotherapyAbstract : Objective : It is unclear how to best sequence adjuvant chemotherapy and radiotherapy for advanced endometrial cancer. We studied the outcomes for women treated with chemotherapy before radiotherapy in a chemotherapy‐first (chemotherapy for 6 cycles followed radiotherapy) or 'sandwich' approach (chemotherapy for 3 cycles followed by radiotherapy and subsequently chemotherapy for 3 cycles). Methods : Women with stage IIIC endometrial cancer and no gross residual disease treated with chemotherapy before radiotherapy between April 2003 and April 2016 were included. The Kaplan‐Meier method was used to estimate recurrence and survival. We performed a meta‐analysis of endometrial cancer trials comparing chemotherapy and radiotherapy versus radiotherapy alone. Results : A total of 102 patients were included. The mean (SD) age was 63.8 (10.6) years; 84 patients received the chemotherapy‐first approach and 18 patients received the 'sandwich' approach. Pelvic and para‐aortic nodes were removed in 99% and 88.2%, respectively. Among all the patients, we observed 1 pelvic (1%), 1 para‐aortic (1%), and 5 vaginal (4.9%) recurrences. At 3 years, for the 'sandwich' and chemotherapy‐first approaches, the vaginal recurrence was 11.8% and 4.2%, pelvic recurrence was 0% and 1.5%, para‐aortic recurrence was 0% and 1.2%, distant recurrence was 42.9% and 24.4%, and overall survival was 70.3% and 81.7%, respectively. With 'chemotherapy before radiotherapy' 94.9% completed 4+ chemotherapy cycles (vs 71‐90% reported in the literature for 'radiotherapy before chemotherapy'). In a meta‐analysis of endometrial cancer trials, distant recurrence rates were reduced with 4+ chemotherapy cycles but not with 3 cycles (p=0.01). Conclusion : Chemotherapy before radiation sequencing for stage IIIC endometrial cancer was associated with a high proportion of patients completing 4+ chemotherapy cycles and low locoregional lymphatic recurrence rate, despite delaying radiotherapy until after 3‐6 cycles of chemotherapy and not administering concurrent cisplatin. … (more)
- Is Part Of:
- International journal of gynecological cancer. Volume 31:Issue 5(2021)
- Journal:
- International journal of gynecological cancer
- Issue:
- Volume 31:Issue 5(2021)
- Issue Display:
- Volume 31, Issue 5 (2021)
- Year:
- 2021
- Volume:
- 31
- Issue:
- 5
- Issue Sort Value:
- 2021-0031-0005-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-05
- Subjects:
- uterine cancer -- radiation
Generative organs, Female -- Cancer -- Periodicals
616.99465 - Journal URLs:
- http://journals.lww.com/ijgc/pages/default.aspx ↗
http://www3.interscience.wiley.com/journal/118544021/toc ↗
https://ijgc.bmj.com/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1136/ijgc-2020-002158 ↗
- Languages:
- English
- ISSNs:
- 1048-891X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 18938.xml